



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1996PLC086581

Date: 25th May, 2026

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code: 524414

Sub.: Intimation under regulation 29 of SEBI (Listing Obligation and Disclosure Requirements), 2015 for holding Board Meeting for approval of Audited financial results for the quarter and year ended March 31, 2026 and other matters.

Dear Sir,

This is to inform you that, the meeting of the Board of Directors of the Company Norris Medicines Limited scheduled to be held on Saturday, 30th May, 2026 at the Registered office of the Company situated at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002, to transact the following business.

1. To consider and approve Audited Financial Results for the quarter and year ended 31st March, 2026 along with Audit Report, Cash Flow Statement, Statement of Asset and Liability and Declaration for un-modified opinion thereof.
2. Any other business with permission of Chair and with the consent of a majority of the Directors present in the Meeting including at least one Independent Director.

Further, as communicated earlier, in accordance with Company's Code of Conduct for Prevention of Insider Trading in securities of the Company and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company is already closed from April 01, 2026 until Forty-Eight (48) hours after declaration of Audited financial results for the quarter ended March 31, 2026 on Stock Exchange.

Kindly take the same on your records.

Thanking You,
Yours truly,

FOR NORRIS MEDICINES LIMITED

VIMAL SHAH
DIRECTOR
DIN: 01506655